283 related articles for article (PubMed ID: 27913493)
21. Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs.
Longley J; Johnson PWM
Curr Oncol Rep; 2021 May; 23(7):76. PubMed ID: 33937922
[TBL] [Abstract][Full Text] [Related]
22. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
23. Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy?
Pettengell R
Drugs; 2009; 69(13):1727-37. PubMed ID: 19719330
[TBL] [Abstract][Full Text] [Related]
24. A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma.
Brandt L; Kimby E; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):213-23. PubMed ID: 11441933
[TBL] [Abstract][Full Text] [Related]
25. Identification of TRA-1-60-positive cells as a potent refractory population in follicular lymphomas.
Takata K; Saito K; Maruyama S; Miyata-Takata T; Iioka H; Okuda S; Ling Y; Karube K; Miki Y; Maeda Y; Yoshino T; Steidl C; Kondo E
Cancer Sci; 2019 Jan; 110(1):443-457. PubMed ID: 30417470
[TBL] [Abstract][Full Text] [Related]
26. Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.
Matarasso S; Assouline S
Future Oncol; 2023 Oct; 19(31):2083-2101. PubMed ID: 37882361
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors in follicular lymphoma: new tools to personalize risk.
Casulo C
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):269-276. PubMed ID: 27913491
[TBL] [Abstract][Full Text] [Related]
28. Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.
Rai S; Inoue H; Sakai K; Hanamoto H; Matsuda M; Maeda Y; Haeno T; Watatani Y; Kumode T; Serizawa K; Taniguchi Y; Hirase C; Espinoza JL; Morita Y; Tanaka H; Ashida T; Tatsumi Y; Nishio K; Matsumura I
Cancer Sci; 2022 Feb; 113(2):660-673. PubMed ID: 34837284
[TBL] [Abstract][Full Text] [Related]
29. Recommendations for Clinical Trial Development in Follicular Lymphoma.
Maddocks K; Barr PM; Cheson BD; Little RF; Baizer L; Kahl BS; Leonard JP; Fowler N; Gordon LI; Link BK; Friedberg JW; Ansell SM
J Natl Cancer Inst; 2017 Mar; 109(3):. PubMed ID: 28040699
[TBL] [Abstract][Full Text] [Related]
30. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
[TBL] [Abstract][Full Text] [Related]
31. Targeting indolent non-Hodgkin lymphoma.
Leslie LA; Skarbnik AP; Bejot C; Stives S; Feldman TA; Goy AH
Expert Rev Hematol; 2017 Apr; 10(4):299-313. PubMed ID: 28277849
[TBL] [Abstract][Full Text] [Related]
32. One Size Does Not Fit All: Who Benefits From Maintenance After Frontline Therapy for Follicular Lymphoma?
Roschewski M; Hill BT
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():467-476. PubMed ID: 31099693
[TBL] [Abstract][Full Text] [Related]
33. Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade.
Apostolidis J; Mokhtar N; Al Omari R; Darweesh M; Al Hashmi H
Hematol Oncol; 2020 Aug; 38(3):213-222. PubMed ID: 31891210
[TBL] [Abstract][Full Text] [Related]
34. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.
Julia E; Salles G
Future Oncol; 2021 Jun; 17(17):2127-2140. PubMed ID: 33709777
[TBL] [Abstract][Full Text] [Related]
35. Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.
Kelly JL; Salles G; Goldman B; Fisher RI; Brice P; Press O; Casasnovas O; Maloney DG; Soubeyran P; Rimsza L; Haioun C; Xerri L; LeBlanc M; Tilly H; Friedberg JW
J Clin Oncol; 2015 May; 33(13):1482-90. PubMed ID: 25823738
[TBL] [Abstract][Full Text] [Related]
36. Purine analogue combinations for indolent lymphomas.
Di Bella N; Ravandi F
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S11-21. PubMed ID: 16549109
[TBL] [Abstract][Full Text] [Related]
37. Targeted treatment and new agents in follicular lymphoma.
Cheson BD
Int J Hematol; 2010 Jul; 92(1):5-11. PubMed ID: 20574673
[TBL] [Abstract][Full Text] [Related]
38. Standard therapies versus novel therapies in Hodgkin lymphoma.
Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
[TBL] [Abstract][Full Text] [Related]
39. Polatuzumab Vedotin: a New Target for B Cell Malignancies.
Choi Y; Diefenbach CS
Curr Hematol Malig Rep; 2020 Apr; 15(2):125-129. PubMed ID: 32172360
[TBL] [Abstract][Full Text] [Related]
40. Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy.
Sohani AR; Maurer MJ; Giri S; Pitcher B; Chadburn A; Said JW; Bartlett NL; Czuczman MS; Martin P; Rosenbaum CA; Jung SH; Leonard JP; Cheson BD; Hsi ED
Am J Surg Pathol; 2021 Mar; 45(3):384-393. PubMed ID: 33136585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]